Pipeline

NKMax is conducting numerous clinical trials to discover how natural killer (NK) cells can help patients with cancer, autoimmune disease and neurodegenerative conditions.

SNK01, NKMax’s first cell therapy candidate, has planned clinical trials in several therapeutic areas, including oncology, autoimmune disease and neurodegeneration. This approach allows us to evaluate the potential benefits of adoptive cellular immunotherapy for multiple biologically relevant disease areas.

Oncology

Preclinical

Phase I

Phase II

Phase III

Stage IV Non Small Cell Lung Cancer

SNK01 + Keytruda (pembrolizumab)

Phase II

Refractory Solid Tumors

Single Agent SNK01

Phase I

Localized/Metastatic Sarcoma (Orphan Disease Status)

Single Agent SNK01

Preclinical

Stage I-III Triple Negative Breast Cancer

Single Agent SNK01

Preclinical

Refractory HER2+Solid Tumors

SNK01 + Herceptin (trastuzumab)

Preclinical

Refractory EGFR + Solid Tumors

SNK01 + Erbitux (cetuximab)

Preclinical

Active
Active
In Planning
In Planning
In Planning
In Planning

Autoimmune Diseases

Preclinical

Phase I

Phase II

Phase III

Mild to Severe Psoriasis

Single Agent SNK01

Phase I

Rheumatoid Arthritis

Single Agent SNK01

Preclinical

Primary Progressive and Relapsing-Remitting Multiple Sclerosis

Single Agent SNK01

Preclinical

Moderate to Severe Psoriasis Refractory to Biologic Therapy

SNK-01 Single Agent

Preclinical

Active
In Planning
In Planning
In Planning

Neurodegenerative Diseases

Preclinical

Phase I

Phase II

Phase III

Mild to Severe Alzheimer’s Disease

Single Agent SNK01

Preclinical

Mild to Severe Alzheimer’s Disease

Single Agent SNK01

In Planning